Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 3, 2012, Pages 253-261

  Betta, Pier Giacomo ^a   Magnani, Corrado ^b   Bensi, Thea ^a   Trincheri, Nicol Francesca ^a   Orecchia, Sara ^a  

^a C Arrigo Children's Hospital   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CHROMOSOME ABERRATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; METABOLISM; METHODOLOGY; MOLECULAR PATHOLOGY; PLEURA TUMOR; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

CHROMOSOME ABERRATIONS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MESOTHELIOMA; PATHOLOGY, MOLECULAR; PLEURAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84858021052     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0604-RA     Document Type: Article

References (57)

1. Nishikawa K, Takahashi K, Karjalainen A, et al. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect. 2008;116(12):1675-1680.
2. Singh G, Whiteside TL, Dekker A. Immunodiagnosis of mesothelioma: use of anti-mesothelial cell serum in an indirect immunofluorescence assay. Cancer. 1979;43(6):2288-2296. (Pubitemid 9246400)
3. Husain A, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2009;133(8):1317-1331.
4. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479-495.
5. Galateau-Salle F, Brambilla E, Cagle PT, et al. Classification and histologic features of epithelioid mesotheliomas. In: Galateau-Salle F, ed. Pathology of Malignant Mesothelioma. London, England: Springer-Verlag; 2006:68-131.
6. ChurgA,Cagle PT, Roggli VL. Tumorsof the Serosal Membranes. Washington, DC: American Registry of Pathology; 2006. Atlas of Tumor Pathology; 4th series, fascicle 3.
7. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21(9):1084-1094.
8. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histologic pattern. Histopathology. 2001;39(6):584-588. (Pubitemid 34017131)
9. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002;15(1):6-10. (Pubitemid 34081453)
10. Lugli A, Forster Y, Haas P, et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol. 2003;34(10):994-1000. (Pubitemid 37315250)
11. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomo-dulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27(2):150-158. (Pubitemid 36152223)
12. Betta PG, Andrion A, Donna A, et al. Malignant mesothelioma of the pleura: the reproducibility of the immunohistologic diagnosis. Pathol Res Pract. 1997;193(11-12):759-765. (Pubitemid 28083304)
13. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothe-lioma: a detailed systematic analysis using published data. Histopathology. 2006; 48(3):223-232.
14. Betta PG. Immunohistochemistry. In: Pass HI, Vogelzang NJ, Carbone M, eds. Malignant Mesothelioma. New York, NY: Springer Science + Business Media;2005:490-507.
15. Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, eds. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press;2004. World Health Organization Classification of Tumours vol 10.
16. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19(4):514-523.
17. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007;57(4):190-199. (Pubitemid 46279947)
18. Klebe S, Nurminen M, Leigh J, Henderson DW. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology. 2009;41(2):140-148.
19. Yuan Y, Nymoen DA, Stavnes HT, et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol. 2009;33(11):1673-1682.
20. Amatya VJ, Takeshima Y, Kohno H, et al. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology. 2009;55(1):10-19.
21. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41(1):20-25.
22. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34(5):627-635.
23. Marchevsky AM, Wick MR. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. Appl Immunohistochem Mol Morphol. 2007;15(2):140-144. (Pubitemid 46828220)
24. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42(3):270-279. (Pubitemid 36356860)
25. Rdzanek M, Fresco R, Pass HI, Carbone M. Spindle cell tumors of the pleura: differential diagnosis. Semin Diagn Pathol. 2006;23(1):44-55 (Pubitemid 44415391)
26. Beasley MB. Immunohistochemistry of pulmonary and pleural neoplasia. Arch Pathol Lab Med. 2008;132(7):1062-1072 (Pubitemid 351955737)
27. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23(3):470-479.
28. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H. D2-40 and calretinin\-a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007;20(2):248-255. (Pubitemid 46422180)
29. Padgett DM, Cathro HP, Wick MR, Mills SE. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 2008;32(1):123-127
30. Takeshima Y, Amatya VJ, Kushitani K, Kaneko M, Inai K. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid meso-thelioma from lung sarcomatoid carcinoma. Histopathology. 2009;54(6):667-676.
31. Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25(5):610-617 (Pubitemid 32423358)
32. Litzky LA. Pulmonary sarcomatous tumors. Arch Pathol Lab Med. 2008; 132(7):1104-1117. (Pubitemid 351955740)
33. Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle-cell neoplasms. Histopathology. 2000;37(3):224-231.
34. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43(3):231-238. (Pubitemid 37115056)
35. Kradin RL, Mark EJ. Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach. Semin Diagn Pathol. 2006;23(1):4-14. (Pubitemid 44415393)
36. Krismann M, Thattamparambil P, Simon F, Johnen G. Praktische Differenzialdiagnose präneoplastischer Veränderungen der Pleura und früher mesothelialer Neoplasien [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings]. Pathologe. 2006;27(2):99-105. (Pubitemid 43341143)
37. Cakir C, Gulluoglu MG, Yilmazbayhan D. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology. 2006;38(1):10-15. (Pubitemid 43259246)
38. Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M, Masjedi MR. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2008; 132(4):694-697. (Pubitemid 351489624)
39. Wu M, Sun Y, Li G, et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol. 2007;128(5):783-787. (Pubitemid 350133989)
40. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215-220. (Pubitemid 46422176)
41. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010;42(2):133-139.
42. Røe OD, Anderssen E, Helge E, et al. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One. 2009;4(8):e6554. doi:10.1371/journal. pone.0006554.
43. Center R, Lukeis R, Dietzsch E, Gillespie M, Garson OM. Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer. 1993;7(1):47-53. (Pubitemid 23141740)
44. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 1993;53(18):4349-4355. (Pubitemid 24146789)
45. Ivanov SV, Miller J, Lucito R, et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer. 2009;124(3):589-599.
46. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Böcking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114(3):204-215. (Pubitemid 351969240)
47. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesothelio-mas. Mod Pathol. 2008;21(6):742-747. (Pubitemid 351744840)
48. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60(5):395-399.
49. Kohno T, Yokota J. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions. DNA Repair (Amst). 2006;5(9-10):1273-1281. (Pubitemid 44291607)
50. Knuuttila A, Jee KJ, Taskinen E, Wolff H, Knuutila S, Anttila S. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch. 2006;448(2):135-141. (Pubitemid 43237878)
51. Chang JW, Huang TH, Wang YC. Emerging methods for analysis of the cancer methylome. Pharmacogenomics. 2008;9(12):1869-1878.
52. Christensen BC, Marsit CJ, Houseman EA, et al. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res. 2009;69(15):6315-6321.
53. Goto Y, Shinjo K, Kondo Y, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23): 9073-9082.
54. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838. (Pubitemid 40839735)
55. Pass HI, Beck A, Hoshen M, et al. Differential microRNA expression in pleural mesothelioma: implications for early detection and prognostication. J Clin Oncol. 2008;26(May 20 suppl): Abstract 11027.
56. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma\-a miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48(7):615-623.
57. Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127(12):2859-2869.